Last reviewed · How we verify

NCT03725436

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Completed Phase 1 Last updated 16 March 2026
What this trial tests

Phase 1 trial testing MDM2/MDMX Inhibitor ALRN-6924 in Advanced Malignant Solid Neoplasm in 28 participants. Completed in 11 March 2026.

Timeline
24 January 2019
Primary endpoint
11 March 2026
11 March 2026

Quick facts

Lead sponsorM.D. Anderson Cancer Center
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment28
Start date24 January 2019
Primary completion11 March 2026
Estimated completion11 March 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Advanced Malignant Solid Neoplasm or Anatomic Stage III Breast Cancer AJCC v8. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase Ib trial studies the side effects and best dose of ALRN-6924 when given together with paclitaxel in treating patients with solid tumors that have spread to other places in the body or cannot be removed by surgery. Drugs used in chemotherapy, such as ALRN-6924 and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Targeting apoptosis in cancer therapy.
    Carneiro BA, El-Deiry WS. · · 2020 · cited 1823× · PMID 32203277 · DOI 10.1038/s41571-020-0341-y
  2. Targeting p53 pathways: mechanisms, structures, and advances in therapy.
    Wang H, Guo M, Wei H, Chen Y. · · 2023 · cited 580× · PMID 36859359 · DOI 10.1038/s41392-023-01347-1
  3. Drugging p53 in cancer: one protein, many targets.
    Hassin O, Oren M. · · 2023 · cited 496× · PMID 36216888 · DOI 10.1038/s41573-022-00571-8
  4. Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.
    Xie X, Yu T, Li X, Zhang N, et al · · 2023 · cited 246× · PMID 37669923 · DOI 10.1038/s41392-023-01589-z
  5. The Role of p53 Signaling in Colorectal Cancer.
    Liebl MC, Hofmann TG. · · 2021 · cited 231× · PMID 33924934 · DOI 10.3390/cancers13092125
  6. Role of p53 in breast cancer progression: An insight into p53 targeted therapy.
    Marvalim C, Datta A, Lee SC. · · 2023 · cited 142× · PMID 36923534 · DOI 10.7150/thno.81847
  7. The role of cell-penetrating peptides in potential anti-cancer therapy.
    Zhou M, Zou X, Cheng K, Zhong S, et al · · 2022 · cited 89× · PMID 35593206 · DOI 10.1002/ctm2.822
  8. MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future.
    Wang W, Albadari N, Du Y, Fowler JF, et al · · 2024 · cited 85× · PMID 38697854 · DOI 10.1124/pharmrev.123.001026

Verify or expand the search:

Other recruiting trials for Advanced Malignant Solid Neoplasm

Currently open trials in the same condition.

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03725436.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing